Table 1.
Clinical and demographic characteristics of the study population.
| Characteristics | n | EWAS of BDR | n | EWAS of FeNO |
|---|---|---|---|---|
| Sex (male) | 121 | 75 (62) | 109 | 67 (61.5) |
| Age (years) | 121 | 12.0 (9.8−14.0) | 109 | 12.1 (9.8−14.0) |
| Ancestry | 121 | 109 | ||
| African | 4 (3.3) | 2 (1.9) | ||
| Asian | 2 (1.7) | 1 (0.9) | ||
| European | 96 (79.3) | 88 (80.7) | ||
| Latin | 9 (7.4) | 8 (7.3) | ||
| Mixed/Other | 10 (8.3) | 10 (9.2) | ||
| Body mass index (z-score) | 121 | 0.5 (−0.3−4.0) | 108 | 0.4 (-0.4−1.3) |
| Uncontrolled asthma | 121 | 77 (63.6) | 109 | 71 (65.1) |
| pre-FEV1 (predicted %) | 121 | 93.6 (82.5−103.2) | 108 | 95.3 (82.7−103.2) |
| pre-FVC (predicted %) | 121 | 99.4 (91.2−108.1) | 108 | 100.3 (91.0−107.6) |
| BDR (%) | 121 | 4.2 (0.6−11.3) | 108 | 4.2 (0.6−10.5) |
| FeNO (ppb) | 120 | 16.0 (9.0−38.0) | 109 | 16.0 (9.0−41.0) |
| SABAs | 103 | 94 (91.3) | 92 | 84 (91.3) |
| LABAs | 103 | 96 (93.2) | 92 | 87 (94.6) |
| ICS | 103 | 103 (100) | 92 | 92 (100) |
| LTRA | 103 | 17 (16.5) | 92 | 15 (16.3) |
| OCS | 103 | 2 (1.9) | 92 | 1 (1.09) |
| Biological therapy † | 103 | 9 (8.7) | 92 | 8 (8.7) |
Categorical variables are described as counts (percentage), and continuous variables as median (interquartile range). † Biological therapy: Mepolizumab or Omalizumab intake. Abbreviations: FEV1: Forced Expiratory Volume in the first second; FVC: forced vital capacity; BDR: Bronchodilator drug response; FeNO: Fractional exhaled nitric oxide; SABA: Short-Acting Beta-Agonists; LABAs: Long-Acting Beta-Agonists; ICS: Inhaled corticosteroids; LTRA: Leukotriene Receptor Antagonists; OCS: Oral corticosteroids.